Private equity firm Frazier Healthcare Partners announced on July 7, 2026, that it has agreed to acquire MatrixCare from medical device maker ResMed. The all-cash transaction values the post-acute care software provider at $1 billion. This divestiture allows ResMed to sharpen its focus on its core connected sleep apnea and respiratory care device business.
Context — [why this matters now]
The acquisition represents a significant consolidation within the healthcare technology sector, specifically targeting post-acute care software. ResMed originally acquired MatrixCare as part of its $750 million purchase of Brightree in 2016, aiming to build a comprehensive out-of-hospital software ecosystem. This move by Frazier arrives during a period of heightened private equity activity in healthcare services, with deal volume up 17% year-over-year in the first half of 2026.
The deal was likely catalyzed by ResMed's strategic review to streamline operations following its major software acquisitions over the past decade. Current macro conditions, with the Federal Funds Target Rate at 4.75%, have made leveraged buyouts more expensive, underscoring the strength of Frazier's commitment to the sector. This transaction highlights the enduring appeal of subscription-based software revenue models in healthcare, which provide predictable cash flows.
Data — [what the numbers show]
The $1 billion price tag represents a multiple of approximately 5x trailing twelve-month revenue, based on MatrixCare's estimated $200 million in annual sales. This valuation slightly exceeds the median multiple of 4.8x for healthcare software deals in the last 18 months. ResMed's software portfolio, which included MatrixCare, generated $1.2 billion in revenue for its fiscal year ending June 2025, accounting for roughly 30% of the company's total sales.
MatrixCare supports over 15,000 post-acute care facilities across North America, including skilled nursing, senior living, and home health agencies. The deal is expected to close in the fourth quarter of 2026, pending customary regulatory approvals. ResMed intends to use the proceeds from the sale to pay down debt and fund share repurchases, potentially reducing its debt-to-equity ratio from 0.45 to below 0.40.
| Metric | Pre-Deal | Post-Deal |
|---|
| ResMed Software Revenue | $1.2B | ~$1.0B |
| Deal Multiple | N/A | ~5x Revenue |
Analysis — [what it means for markets / sectors / tickers]
The transaction is a clear positive for ResMed (RMD) as it allows management to focus on higher-margin core hardware and digital health businesses, potentially improving operating margins by 150-200 basis points. The deal removes a segment that was growing slower than its device business. Private equity ownership under Frazier could accelerate MatrixCare's growth through operational improvements and add-on acquisitions in the fragmented post-acute care market.
A counter-argument exists that ResMed is selling a valuable software asset that provided revenue diversification and cross-selling opportunities with its device customers. Competitors in the healthcare IT space, such as Netsmart and PointClickCare, may face increased competitive pressure from a privately-owned MatrixCare focused solely on growth. Investment flows are likely shifting toward pure-play healthcare services and tech names, as seen in recent strength in the XHE healthcare equipment ETF.
Outlook — [what to watch next]
Market participants should monitor ResMed's Q4 FY2026 earnings call on July 24, 2026, for updated financial guidance excluding MatrixCare. Key levels to watch include RMD's 200-day moving average at $215, which could serve as technical support post-deal announcement. The closing of the transaction, expected in Q4 2026, is the next definitive catalyst.
Regulatory scrutiny from the FTC regarding consolidation in the healthcare software market represents a potential, though low-probability, risk to deal completion. Future performance of the remaining ResMed software business, primarily SaaS revenue from its AirView platform, will be critical in assessing the long-term wisdom of the divestiture. A successful integration by Frazier could set the stage for a future IPO of MatrixCare in 3-5 years.
Frequently Asked Questions
What does the MatrixCare sale mean for ResMed investors?
The sale simplifies ResMed's story for investors, transforming it into a more focused medical device and digital health company. It immediately strengthens the balance sheet, providing capital for buybacks and debt reduction. The divestiture allows analysts to value RMD on its higher-growth, higher-margin core businesses, potentially leading to a higher earnings multiple. The loss of diversified software revenue is a trade-off for improved strategic clarity.
How does this acquisition compare to other recent healthcare IT deals?
The 5x revenue multiple paid by Frazier is moderately rich compared to the 4.3x multiple Thoma Bravo paid for NextGen Healthcare in 2023. It reflects the premium assigned to MatrixCare's extensive market share in skilled nursing facility software. This deal is larger than most middle-market healthcare IT transactions but smaller than mega-deals like Oracle's purchase of Cerner, indicating strong confidence in a specific niche of the healthcare software market.
Will Frazier Healthcare Partners make significant changes to MatrixCare?
Private equity owners typically focus on operational efficiency and growth initiatives. Expect Frazier to conduct a thorough review of MatrixCare's cost structure and potentially consolidate redundant roles. Strategic changes may include investing more aggressively in sales and marketing to capture market share and pursuing tuck-in acquisitions of smaller post-acute care software providers to build scale. The core product and customer support are unlikely to see immediate drastic changes.
Bottom Line
ResMed's strategic retreat from post-acute care software unlocks value for a focused growth narrative.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
